Browse CDK2

Summary
SymbolCDK2
Namecyclin-dependent kinase 2
Aliases p33(CDK2); cell division protein kinase 2; p33 protein kinase
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Nucleus, Cajal body. Cytoplasm. Endosome. Note=Localized at the centrosomes in late G2 phase after separation of the centrosomes but before the start of prophase. Nuclear-cytoplasmic trafficking is mediated during the inhibition by 1,25-(OH)(2)D(3).
Domain PF00069 Protein kinase domain
Function

Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in human embryonic stem cells (hESCs). Activity of CDK2 is maximal during S phase and G2; activated by interaction with cyclin E during the early stages of DNA synthesis to permit G1-S transition, and subsequently activated by cyclin A2 (cyclin A1 in germ cells) during the late stages of DNA replication to drive the transition from S phase to mitosis, the G2 phase. EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing. Phosphorylates CABLES1 (By similarity). Cyclin E/CDK2 prevents oxidative stress-mediated Ras-induced senescence by phosphorylating MYC. Involved in G1-S phase DNA damage checkpoint that prevents cells with damaged DNA from initiating mitosis; regulates homologous recombination-dependent repair by phosphorylating BRCA2, this phosphorylation is low in S phase when recombination is active, but increases as cells progress towards mitosis. In response to DNA damage, double-strand break repair by homologous recombination a reduction of CDK2-mediated BRCA2 phosphorylation. Phosphorylation of RB1 disturbs its interaction with E2F1. NPM1 phosphorylation by cyclin E/CDK2 promotes its dissociates from unduplicated centrosomes, thus initiating centrosome duplication. Cyclin E/CDK2-mediated phosphorylation of NPAT at G1-S transition and until prophase stimulates the NPAT-mediated activation of histone gene transcription during S phase. Required for vitamin D-mediated growth inhibition by being itself inactivated. Involved in the nitric oxide- (NO) mediated signaling in a nitrosylation/activation-dependent manner. USP37 is activated by phosphorylation and thus triggers G1-S transition. CTNNB1 phosphorylation regulates insulin internalization. Phosphorylates FOXP3 and negatively regulates its transcriptional activity and protein stability (By similarity). Phosphorylates CDK2AP2 (PubMed:12944431).

> Gene Ontology
 
Biological Process GO:0000075 cell cycle checkpoint
GO:0000077 DNA damage checkpoint
GO:0000082 G1/S transition of mitotic cell cycle
GO:0000086 G2/M transition of mitotic cell cycle
GO:0000226 microtubule cytoskeleton organization
GO:0000302 response to reactive oxygen species
GO:0006260 DNA replication
GO:0006261 DNA-dependent DNA replication
GO:0006270 DNA replication initiation
GO:0006275 regulation of DNA replication
GO:0006813 potassium ion transport
GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest
GO:0006979 response to oxidative stress
GO:0007050 cell cycle arrest
GO:0007067 mitotic nuclear division
GO:0007093 mitotic cell cycle checkpoint
GO:0007098 centrosome cycle
GO:0007099 centriole replication
GO:0007126 meiotic nuclear division
GO:0007265 Ras protein signal transduction
GO:0007346 regulation of mitotic cell cycle
GO:0010035 response to inorganic substance
GO:0010948 negative regulation of cell cycle process
GO:0015672 monovalent inorganic cation transport
GO:0016458 gene silencing
GO:0016570 histone modification
GO:0016572 histone phosphorylation
GO:0018105 peptidyl-serine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0030174 regulation of DNA-dependent DNA replication initiation
GO:0030330 DNA damage response, signal transduction by p53 class mediator
GO:0031023 microtubule organizing center organization
GO:0031396 regulation of protein ubiquitination
GO:0031397 negative regulation of protein ubiquitination
GO:0031570 DNA integrity checkpoint
GO:0031571 mitotic G1 DNA damage checkpoint
GO:0032298 positive regulation of DNA-dependent DNA replication initiation
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0042770 signal transduction in response to DNA damage
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044773 mitotic DNA damage checkpoint
GO:0044774 mitotic DNA integrity checkpoint
GO:0044783 G1 DNA damage checkpoint
GO:0044819 mitotic G1/S transition checkpoint
GO:0044839 cell cycle G2/M phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045740 positive regulation of DNA replication
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0045930 negative regulation of mitotic cell cycle
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051297 centrosome organization
GO:0051298 centrosome duplication
GO:0051321 meiotic cell cycle
GO:0051348 negative regulation of transferase activity
GO:0051436 negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle
GO:0051438 regulation of ubiquitin-protein transferase activity
GO:0051439 regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle
GO:0051444 negative regulation of ubiquitin-protein transferase activity
GO:0060968 regulation of gene silencing
GO:0071156 regulation of cell cycle arrest
GO:0071158 positive regulation of cell cycle arrest
GO:0071241 cellular response to inorganic substance
GO:0071731 response to nitric oxide
GO:0071732 cellular response to nitric oxide
GO:0072331 signal transduction by p53 class mediator
GO:0072395 signal transduction involved in cell cycle checkpoint
GO:0072401 signal transduction involved in DNA integrity checkpoint
GO:0072413 signal transduction involved in mitotic cell cycle checkpoint
GO:0072422 signal transduction involved in DNA damage checkpoint
GO:0072431 signal transduction involved in mitotic G1 DNA damage checkpoint
GO:0090068 positive regulation of cell cycle process
GO:0090329 regulation of DNA-dependent DNA replication
GO:0098534 centriole assembly
GO:1901796 regulation of signal transduction by p53 class mediator
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902170 cellular response to reactive nitrogen species
GO:1902400 intracellular signal transduction involved in G1 DNA damage checkpoint
GO:1902402 signal transduction involved in mitotic DNA damage checkpoint
GO:1902403 signal transduction involved in mitotic DNA integrity checkpoint
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:1903046 meiotic cell cycle process
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903321 negative regulation of protein modification by small protein conjugation or removal
GO:1904666 regulation of ubiquitin protein ligase activity
GO:1904667 negative regulation of ubiquitin protein ligase activity
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000105 positive regulation of DNA-dependent DNA replication
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004693 cyclin-dependent protein serine/threonine kinase activity
GO:0030332 cyclin binding
GO:0035173 histone kinase activity
GO:0097472 cyclin-dependent protein kinase activity
Cellular Component GO:0000307 cyclin-dependent protein kinase holoenzyme complex
GO:0000781 chromosome, telomeric region
GO:0000793 condensed chromosome
GO:0000803 sex chromosome
GO:0000805 X chromosome
GO:0000806 Y chromosome
GO:0005667 transcription factor complex
GO:0005813 centrosome
GO:0015030 Cajal body
GO:0016604 nuclear body
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0098687 chromosomal region
GO:1902554 serine/threonine protein kinase complex
GO:1902911 protein kinase complex
> KEGG and Reactome Pathway
 
KEGG hsa04068 FoxO signaling pathway
hsa04110 Cell cycle
hsa04114 Oocyte meiosis
hsa04115 p53 signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04914 Progesterone-mediated oocyte maturation
Reactome R-HSA-174143: APC/C-mediated degradation of cell cycle proteins
R-HSA-176187: Activation of ATR in response to replication stress
R-HSA-68962: Activation of the pre-replicative complex
R-HSA-69017: CDK-mediated phosphorylation and removal of Cdc6
R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-69273: Cyclin A/B1 associated events during G2/M transition
R-HSA-69656: Cyclin A
R-HSA-69202: Cyclin E associated events during G1/S transition
R-HSA-2559586: DNA Damage/Telomere Stress Induced Senescence
R-HSA-5693532: DNA Double-Strand Break Repair
R-HSA-73894: DNA Repair
R-HSA-69306: DNA Replication
R-HSA-69002: DNA Replication Pre-Initiation
R-HSA-983231: Factors involved in megakaryocyte development and platelet production
R-HSA-1538133: G0 and Early G1
R-HSA-69615: G1/S DNA Damage Checkpoints
R-HSA-69206: G1/S Transition
R-HSA-68911: G2 Phase
R-HSA-69481: G2/M Checkpoints
R-HSA-69275: G2/M Transition
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-5693567: HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA)
R-HSA-109582: Hemostasis
R-HSA-5693538: Homology Directed Repair
R-HSA-68874: M/G1 Transition
R-HSA-1500620: Meiosis
R-HSA-912446: Meiotic recombination
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-453274: Mitotic G2-G2/M phases
R-HSA-68949: Orc1 removal from chromatin
R-HSA-8849470: PTK6 Regulates Cell Cycle
R-HSA-69200: Phosphorylation of proteins involved in G1/S transition by active Cyclin E
R-HSA-5693607: Processing of DNA double-strand break ends
R-HSA-176408: Regulation of APC/C activators between G1/S and early anaphase
R-HSA-69304: Regulation of DNA replication
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation
R-HSA-6804757: Regulation of TP53 Degradation
R-HSA-6806003: Regulation of TP53 Expression and Degradation
R-HSA-453276: Regulation of mitotic cell cycle
R-HSA-69300: Removal of licensing factors from origins
R-HSA-69242: S Phase
R-HSA-187577: SCF(Skp2)-mediated degradation of p27/p21
R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP)
R-HSA-162582: Signal Transduction
R-HSA-8848021: Signaling by PTK6
R-HSA-69052: Switching of origins to a post-replicative state
R-HSA-69239: Synthesis of DNA
R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes
R-HSA-6804116: TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-69563: p53-Dependent G1 DNA Damage Response
R-HSA-69580: p53-Dependent G1/S DNA damage checkpoint
Summary
SymbolCDK2
Namecyclin-dependent kinase 2
Aliases p33(CDK2); cell division protein kinase 2; p33 protein kinase
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CDK2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCDK2
Namecyclin-dependent kinase 2
Aliases p33(CDK2); cell division protein kinase 2; p33 protein kinase
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CDK2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.37; FDR: 0.04170 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCDK2
Namecyclin-dependent kinase 2
Aliases p33(CDK2); cell division protein kinase 2; p33 protein kinase
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CDK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3660.575
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8930.762
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0420.987
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5050.0689
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8420.589
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0790.968
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0040.995
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2290.917
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1920.936
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3530.791
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6890.73
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.330.000251
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CDK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCDK2
Namecyclin-dependent kinase 2
Aliases p33(CDK2); cell division protein kinase 2; p33 protein kinase
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CDK2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCDK2
Namecyclin-dependent kinase 2
Aliases p33(CDK2); cell division protein kinase 2; p33 protein kinase
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CDK2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CDK2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCDK2
Namecyclin-dependent kinase 2
Aliases p33(CDK2); cell division protein kinase 2; p33 protein kinase
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CDK2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCDK2
Namecyclin-dependent kinase 2
Aliases p33(CDK2); cell division protein kinase 2; p33 protein kinase
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CDK2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCDK2
Namecyclin-dependent kinase 2
Aliases p33(CDK2); cell division protein kinase 2; p33 protein kinase
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CDK2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCDK2
Namecyclin-dependent kinase 2
Aliases p33(CDK2); cell division protein kinase 2; p33 protein kinase
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CDK2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CDK2.
ID Name Drug Type Targets #Targets
DB018884-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-DimethylbenzenesulfonamideSmall MoleculeCDK21
DB02010StaurosporineSmall MoleculeCDK2, CHRM1, CSK, GSK3B, ITK, LCK, MAPKAPK2, PDPK1, PIK3CG, PIM1, ......13
DB02052Indirubin-3'-MonoximeSmall MoleculeAHR, CDK1, CDK2, CDK5, CDK5R1, GSK3B6
DB020914-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-YlamineSmall MoleculeCCNA2, CDK22
DB02116OlomoucineSmall MoleculeCDK1, CDK2, CDK5, MAPK14
DB021974-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]BenzenesulfonamideSmall MoleculeCDK21
DB022972-Amino-6-ChloropyrazineSmall MoleculeCDK21
DB024076-O-Cyclohexylmethyl GuanineSmall MoleculeCCNA2, CDK22
DB02538N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]AcetamideSmall MoleculeCDK21
DB026031-Amino-6-Cyclohex-3-EnylmethyloxypurineSmall MoleculeCDK21
DB02647N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)BenzamideSmall MoleculeCDK21
DB02733PurvalanolSmall MoleculeCDK2, CDK4, MAPK1, MAPK3, SRPK25
DB02833[4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-AmineSmall MoleculeCCNA2, CDK22
DB028985-{[(2-Amino-9h-Purin-6-Yl)Oxy]Methyl}-2-PyrrolidinoneSmall MoleculeCDK21
DB029154-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamineSmall MoleculeCCNA2, CDK22
DB02950HymenialdisineSmall MoleculeCDK1, CDK2, CDK53
DB02963(5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)AmineSmall MoleculeCDK21
DB029734-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-BenzenesulfonamideSmall MoleculeCDK21
DB030194-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-YlamineSmall MoleculeCDK21
DB033074-[(6-Amino-4-Pyrimidinyl)Amino]BenzenesulfonamideSmall MoleculeCDK21
DB033654-[3-Hydroxyanilino]-6,7-DimethoxyquinazolineSmall MoleculeCDK21
DB03428SU9516Small MoleculeCDK1, CDK2, CDK53
DB034903-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]PyrazoleSmall MoleculeCDK21
DB03496AlvocidibSmall MoleculeCDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGB, PYGL, ......12
DB03583(2e,3s)-3-Hydroxy-5'-[(4-Hydroxypiperidin-1-Yl)Sulfonyl]-3-Methyl-1,3-Dihydro-2,3'-Biindol-2'(1'h)-OneSmall MoleculeCDK21
DB036631-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-ButanolSmall MoleculeCDK21
DB037374-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-OneSmall MoleculeCDK21
DB03801Lysine Nz-Carboxylic AcidSmall MoleculeCDK21
DB04006[2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-MethanoneSmall MoleculeCDK21
DB04101N-[4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl]-N'-HydroxyimidoformamideSmall MoleculeCDK21
DB04186N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)UreaSmall MoleculeCDK21
DB042882-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-CyclopentylpurineSmall MoleculeCDK21
DB044074-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-PhenolSmall MoleculeCDK21
DB045183-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-PhenolSmall MoleculeCDK21
DB04607PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINESmall MoleculeCDK21
DB04662OLOMOUCINE IISmall MoleculeCDK21
DB04669TRIAZOLOPYRIMIDINESmall MoleculeCDK21
DB05037AT7519Small MoleculeCDK1, CDK22
DB06195SeliciclibSmall MoleculeCDK1, CDK2, CDK7, CDK9, CSNK1E, MAPK1, MAPK37
DB06616BosutinibSmall MoleculeABL1, BCR, CAMK2G, CDK2, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, SRC10
DB068444-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDESmall MoleculeCCNA2, CDK22
DB06888(13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONESmall MoleculeCDK21
DB06944N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamideSmall MoleculeCCNA2, CDK22
DB069482-ANILINO-6-CYCLOHEXYLMETHOXYPURINESmall MoleculeCCNA2, CDK22
DB069761-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREASmall MoleculeCDK21
DB06983(5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanolSmall MoleculeCDK21
DB070242-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONESmall MoleculeCDK21
DB07054(2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OLSmall MoleculeCDK21
DB070655-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amineSmall MoleculeCDK21
DB07126O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINESmall MoleculeCCNA2, CDK22
DB07137(2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDESmall MoleculeCCNA2, CDK22
DB071635-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONESmall MoleculeCDK21
DB07164N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amineSmall MoleculeCCNA2, CDK22
DB071793-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxideSmall MoleculeCDK21
DB072036-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINESmall MoleculeCCNA2, CDK22
DB072103-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amineSmall MoleculeCDK21
DB07220N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDESmall MoleculeCDK21
DB07431(3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-oneSmall MoleculeCDK2, MAPKAPK22
DB074715-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDESmall MoleculeCCNA2, CDK22
DB07493(2Z)-5'-BROMO-2,3'-BIINDOLE-2',3(1H,1'H)-DIONE AMMONIATESmall MoleculeCDK21
DB07501(2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanolSmall MoleculeCDK21
DB07504(2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanolSmall MoleculeCDK21
DB075292-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONESmall MoleculeCDK21
DB075314-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDESmall MoleculeCDK21
DB075334-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDESmall MoleculeCCNA2, CDK22
DB075344-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDESmall MoleculeCCNA2, CDK22
DB075384-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDESmall MoleculeCCNA2, CDK22
DB075394-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACIDSmall MoleculeCCNA2, CDK22
DB075404-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDESmall MoleculeCDK21
DB07562N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINESmall MoleculeCCNA2, CDK22
DB07595(5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINESmall MoleculeCDK21
DB076066-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONESmall MoleculeCDK21
DB076126-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINESmall MoleculeCDK21
DB076182-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDESmall MoleculeCDK21
DB076221-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREASmall MoleculeCDK21
DB076854-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDESmall MoleculeCDK21
DB076864-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDESmall MoleculeCDK21
DB076874-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDESmall MoleculeCDK21
DB076884-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDESmall MoleculeCCNA2, CDK22
DB077314-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOLSmall MoleculeCDK21
DB07750(2R)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanolSmall MoleculeCDK21
DB07751(2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanolSmall MoleculeCDK21
DB07755(2S)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanolSmall MoleculeCDK21
DB07761(2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanolSmall MoleculeCDK21
DB07790N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDESmall MoleculeCDK21
DB077914-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDESmall MoleculeCDK21
DB078521-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACIDSmall MoleculeCCNA2, CDK22
DB07889(2S)-1-(Dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanolSmall MoleculeCDK21
DB07936N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amineSmall MoleculeCDK21
DB079822-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanolSmall MoleculeCDK21
DB08066N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDESmall MoleculeAURKA, CDK22
DB08094(4-AMINO-2-{[1-(METHYLSULFONYL)PIPERIDIN-4-YL]AMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONESmall MoleculeCDK21
DB08122N-METHYL-4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDESmall MoleculeCDK21
DB08123N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDESmall MoleculeCDK21
DB081243-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONESmall MoleculeCDK21
DB081254-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDESmall MoleculeCDK21
DB081263-{[4-([AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLESmall MoleculeCDK21
DB081325-hydroxynaphthalene-1-sulfonamideSmall MoleculeCDK21
DB08133N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamideSmall MoleculeCDK21
DB081344-[(6-chloropyrazin-2-yl)amino]benzenesulfonamideSmall MoleculeCDK21
DB08135N-phenyl-1H-pyrazole-3-carboxamideSmall MoleculeCDK21
DB081364-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamideSmall MoleculeCDK21
DB08137(4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamideSmall MoleculeCDK21
DB08138{[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamideSmall MoleculeCDK21
DB081395-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrileSmall MoleculeCDK21
DB081405-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILESmall MoleculeCDK21
DB081414-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamideSmall MoleculeCDK21
DB081424-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamideSmall MoleculeCDK21
DB081784-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amineSmall MoleculeCCNA2, CDK22
DB081824-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amineSmall MoleculeCCNA2, CDK22
DB08218HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUMSmall MoleculeCCNA2, CDK22
DB082194-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINESmall MoleculeCCNA2, CDK22
DB082336-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINESmall MoleculeCCNA2, CDK22
DB082414-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDESmall MoleculeCCNA2, CDK22
DB082476-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINESmall MoleculeCDK21
DB082483-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDESmall MoleculeCCNA2, CDK22
DB08285(2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-olSmall MoleculeCCNA2, CDK22
DB083093-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OLSmall MoleculeCCNA2, CDK22
DB083126-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINESmall MoleculeCDK21
DB083551-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acidSmall MoleculeCCNA2, CDK22
DB084416-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDESmall MoleculeCDK21
DB08463(2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-olSmall MoleculeCCNA2, CDK22
DB085271-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDESmall MoleculeCCNA2, CDK22
DB085315-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amineSmall MoleculeCDK21
DB085326-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amineSmall MoleculeCDK21
DB085333-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amineSmall MoleculeCDK21
DB085345-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amineSmall MoleculeCDK21
DB085353-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amineSmall MoleculeCDK21
DB085363-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amineSmall MoleculeCDK21
DB085373-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amineSmall MoleculeCDK21
DB08538N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amineSmall MoleculeCDK21
DB085393-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amineSmall MoleculeCDK21
DB085724-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDESmall MoleculeCCNA2, CDK22
DB086734-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDESmall MoleculeCDK21
DB08677N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDESmall MoleculeCDK21
DB086949-amino-5-(2-aminopyrimidin-4-yl)pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-olSmall MoleculeCCNA2, CDK22
DB08768N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINESmall MoleculeCDK21